Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;10(2):378. doi: 10.3390/cells10020378

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Ki-67 and ß-catenin (CTNNB1) expression in resected human breast cancer brain metastases. Double-labeling immunofluorescence analysis was performed in tissue sections from breast cancer brain metastases representative of each myocyte enhancer factor 2C (MEF2C) expression phenotype (P1, P2, and P3). Analysis of the proliferation marker Ki-67 (red) in metastases labeled with β-catenin (yellow) revealed the presence of Ki-67 positive cells at the periphery of metastasis in which β-catenin was mainly expressed at the cell membrane (corresponding to MEF2C P1), as well as an increasing number of Ki-67 positive cells and their presence inside metastases as β-catenin dislocated to the cytosol and nucleus (corresponding to MEF2C P2 and P3). Ten fields of one representative section of each MEF2C phenotype were analyzed.